QOP
SPRY icon

Quinn Opportunity Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Quinn Opportunity Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.4M Buy
175,000
+20,000
+13% +$172K 0.07% 201
2026
Q1 		$1.24M Hold
155,000
– – 0.06% 197
2025
Q4 		$1.81M Buy
155,000
+30,000
+24% +$292K 0.08% 185
2025
Q3 		$1.26M Buy
125,000
+80,000
+178% +$1.15M 0.09% 169
2025
Q2 		$785K Sell
45,000
-66,628
-60% -$961K 0.07% 208
2025
Q1 		$1.4M Buy
+111,628
New +$1.34M 0.1% 187

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Quinn Opportunity Partners's SPRY Position: Q2 2026 in Review

Quinn Opportunity Partners increased its ARS Pharmaceuticals (SPRY) stake by 13% in Q2 2026, buying an estimated $172K and bringing the position to 175,000 shares worth $1.4M. The position accounts for 0.07% of the portfolio, ranked #201.

Quinn Opportunity Partners first reported a position in SPRY in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.81M in Q4 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Quinn Opportunity Partners held 175,000 shares of ARS Pharmaceuticals worth $1.4M as of Q2 2026.
  • Quinn Opportunity Partners bought 20,000 ARS Pharmaceuticals shares in Q2 2026, an estimated $172K.
  • ARS Pharmaceuticals made up 0.07% of Quinn Opportunity Partners's portfolio in Q2 2026, its #201 holding.
  • Quinn Opportunity Partners first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Quinn Opportunity Partners's ARS Pharmaceuticals position peaked at $1.81M in Q4 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Quinn Opportunity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.